Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Canales-Albendea, M. A. (Miguel Ángel) | - |
dc.creator | Hiddemann, W. (Wolfgang) | - |
dc.creator | Barbui, A. M. (Anna Maria) | - |
dc.creator | Cannell, P. K. (Paul K.) | - |
dc.creator | Collins, G. P. (Graham P.) | - |
dc.creator | Dürig, J. (Jan) | - |
dc.creator | Forstpointner, R. (Roswitha) | - |
dc.creator | Herold, M. (Michael) | - |
dc.creator | Hertzberg, M. (Mark) | - |
dc.creator | Klanova, M. (Magdalena) | - |
dc.creator | Radford, J. (John) | - |
dc.creator | Seymour, J.F. (John F.) | - |
dc.creator | Tobinai, K. (Kensei) | - |
dc.creator | Trotman, J. (Judith) | - |
dc.creator | Burciu, A. (Alis) | - |
dc.creator | Fingerle-Rowson, G. (Günter) | - |
dc.creator | Wolbers, M. (Marcel) | - |
dc.creator | Nielsen, T.G. (Tina G.) | - |
dc.creator | Marcus, R. E. (Robert E.) | - |
dc.date.accessioned | 2024-01-29T11:38:12Z | - |
dc.date.available | 2024-01-29T11:38:12Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | Canales-Albendea, M. A. (Miguel Ángel); Hiddemann, W. (Wolfgang); Barbui, A. M. (Anna Maria); et al. "Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety". Journal of Clinical Oncology. 36 (23), 2018, 2395 - 2406 | es_ES |
dc.identifier.uri | https://hdl.handle.net/10171/68609 | - |
dc.description.abstract | Purpose; The GALLIUM study (ClinicalTrials.gov identifier: NCT01332968) showed that obinutuzumab (GA101; G) significantly prolonged progression-free survival (PFS) in previously untreated patients with follicular lymphoma relative to rituximab (R) when combined with cyclophosphamide (C), doxorubicin, vincristine (V), and prednisone (P; CHOP); CVP; or bendamustine. This report focuses on the impact of chemotherapy backbone on efficacy and safety. Patients and Methods: A total of 1,202 patients with previously untreated follicular lymphoma (grades 1 to 3a), advanced disease (stage III or IV, or stage II with tumor diameter $ 7 cm), Eastern Cooperative Oncology Group performance status 0 to 2, and requiring treatment were randomly assigned 1:1 to G 1,000 mg on days 1, 8, and 15 of cycle 1 and day 1 of subsequent cycles or R 375 mg/m2 on day 1 of each cycle, for six to eight cycles, depending on chemotherapy (allocated nonrandomly by center). Responding patients received G or R for 2 years or until disease progression. Results: Baseline Follicular Lymphoma International Prognostic Index risk, bulky disease, and comorbidities differed by chemotherapy. After 41.1 months median follow-up, PFS (primary end point) was superior for G plus chemotherapy (overall hazard ratio [HR], 0.68; 95% CI, 0.54 to 0.87; P= .0016), with consistent results across chemotherapy backbones (bendamustine: HR, 0.63; 95% CI, 0.46 to 0.88; CHOP: HR, 0.72; 95% CI, 0.48 to 1.10; CVP: HR, 0.79; 95% CI, 0.42 to 1.47). Grade 3 to 5 adverse events, notably cytopenias, were most frequent with CHOP. Grade 3 to 5 infections and second neoplasms were most frequent with bendamustine, which was associated with marked and prolonged reductions in T-cell counts. Fatal events were more frequent in patients treated with bendamustine, possibly reflecting differences in patient risk profiles. Conclusion: Improved PFS was observed for G plus chemotherapy for all three chemotherapy backbones. Safety profiles differed, although comparisons are confounded by nonrandom chemotherapy allocation. | es_ES |
dc.language.iso | eng | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | GALLIUM | es_ES |
dc.subject | Obinutuzumab | es_ES |
dc.subject | Progression-free survival | es_ES |
dc.subject | Follicular lymphoma | es_ES |
dc.subject | Cyclophosphamide | es_ES |
dc.subject | Doxorubicin | es_ES |
dc.subject | Vincristine | es_ES |
dc.subject | Prednisone | es_ES |
dc.subject | Bendamustine | es_ES |
dc.title | Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.editorial.note | © 2018 by American Society of Clinical Oncology. Creative Commons Attribution Non-Commercial No Derivatives 4.0 License | es_ES |
dadun.citation.endingPage | 2406 | es_ES |
dadun.citation.number | 23 | es_ES |
dadun.citation.publicationName | Journal of Clinical Oncology | es_ES |
dadun.citation.startingPage | 2395 | es_ES |
dadun.citation.volume | 36 | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.